1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Thrombocythaemia Myelofibrosis - Pipeline Review, H1 2016

Thrombocythaemia Myelofibrosis - Pipeline Review, H1 2016

  • February 2016
  • -
  • Global Markets Direct
  • -
  • 65 pages

Thrombocythaemia Myelofibrosis - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Thrombocythaemia Myelofibrosis - Pipeline Review, H1 2016’, provides an overview of the Thrombocythaemia Myelofibrosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Thrombocythaemia Myelofibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Thrombocythaemia Myelofibrosis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Thrombocythaemia Myelofibrosis
- The report reviews pipeline therapeutics for Thrombocythaemia Myelofibrosis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Thrombocythaemia Myelofibrosis therapeutics and enlists all their major and minor projects
- The report assesses Thrombocythaemia Myelofibrosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Thrombocythaemia Myelofibrosis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Thrombocythaemia Myelofibrosis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Thrombocythaemia Myelofibrosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Thrombocythaemia Myelofibrosis - Pipeline Review, H1 2016
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Thrombocythaemia Myelofibrosis Overview 6
Therapeutics Development 7
Pipeline Products for Thrombocythaemia Myelofibrosis - Overview 7
Thrombocythaemia Myelofibrosis - Therapeutics under Development by Companies 8
Thrombocythaemia Myelofibrosis - Pipeline Products Glance 9
Late Stage Products 9
Clinical Stage Products 10
Thrombocythaemia Myelofibrosis - Products under Development by Companies 11
Thrombocythaemia Myelofibrosis - Companies Involved in Therapeutics Development 12
Celgene Corporation 12
Gilead Sciences, Inc. 13
Incyte Corporation 14
JW Pharmaceutical Corporation 15
MEI Pharma, Inc. 16
Nippon Shinyaku Co., Ltd. 17
Novartis AG 18
Pfizer Inc. 19
Thrombocythaemia Myelofibrosis - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 28
buparlisib hydrochloride - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
CWP-291 - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
glasdegib - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
INCB-39110 - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
momelotinib dihydrochloride - Drug Profile 38
Product Description 38
Mechanism of Action 38
RandD Progress 38
NS-018 - Drug Profile 41
Product Description 41
Mechanism of Action 41
RandD Progress 41
pomalidomide - Drug Profile 42
Product Description 42
Mechanism of Action 42
RandD Progress 42
pracinostat - Drug Profile 46
Product Description 46
Mechanism of Action 46
RandD Progress 46
Thrombocythaemia Myelofibrosis - Recent Pipeline Updates 48
Thrombocythaemia Myelofibrosis - Dormant Projects 62
Thrombocythaemia Myelofibrosis - Discontinued Products 63
Appendix 64
Methodology 64
Coverage 64
Secondary Research 64
Primary Research 64
Expert Panel Validation 64
Contact Us 64
Disclaimer 65

List of Tables
Number of Products under Development for Thrombocythaemia Myelofibrosis, H1 2016 7
Number of Products under Development by Companies, H1 2016 8
Comparative Analysis by Late Stage Development, H1 2016 9
Comparative Analysis by Clinical Stage Development, H1 2016 10
Products under Development by Companies, H1 2016 11
Thrombocythaemia Myelofibrosis - Pipeline by Celgene Corporation, H1 2016 12
Thrombocythaemia Myelofibrosis - Pipeline by Gilead Sciences, Inc., H1 2016 13
Thrombocythaemia Myelofibrosis - Pipeline by Incyte Corporation, H1 2016 14
Thrombocythaemia Myelofibrosis - Pipeline by JW Pharmaceutical Corporation, H1 2016 15
Thrombocythaemia Myelofibrosis - Pipeline by MEI Pharma, Inc., H1 2016 16
Thrombocythaemia Myelofibrosis - Pipeline by Nippon Shinyaku Co., Ltd., H1 2016 17
Thrombocythaemia Myelofibrosis - Pipeline by Novartis AG, H1 2016 18
Thrombocythaemia Myelofibrosis - Pipeline by Pfizer Inc., H1 2016 19
Assessment by Monotherapy Products, H1 2016 20
Number of Products by Stage and Target, H1 2016 22
Number of Products by Stage and Mechanism of Action, H1 2016 24
Number of Products by Stage and Route of Administration, H1 2016 26
Number of Products by Stage and Molecule Type, H1 2016 27
Thrombocythaemia Myelofibrosis Therapeutics - Recent Pipeline Updates, H1 2016 48
Thrombocythaemia Myelofibrosis - Dormant Projects, H1 2016 62
Thrombocythaemia Myelofibrosis - Discontinued Products, H1 2016 63

List of Figures
Number of Products under Development for Thrombocythaemia Myelofibrosis, H1 2016 7
Number of Products under Development by Companies, H1 2016 8
Comparative Analysis by Clinical Stage Development, H1 2016 10
Assessment by Monotherapy Products, H1 2016 20
Number of Products by Top 10 Targets, H1 2016 21
Number of Products by Stage and Top 10 Targets, H1 2016 21
Number of Products by Top 10 Mechanism of Actions, H1 2016 23
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 23
Number of Products by Routes of Administration, H1 2016 25
Number of Products by Stage and Routes of Administration, H1 2016 25
Number of Products by Stage and Molecule Types, H1 2016 27

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Tyrosine Protein Kinase Me ...

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Pipeline Review, H2 2016

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) ...

Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) - Pipeline Review, H2 2016

Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • October 2016
  • by Global Markets Direct

Lysine Specific Histone Demethylase 1A (Lysine (K) Specific Demethylase 1 or Flavin Containing Amine Oxidase Domain Containing Protein 2 or BRAF35 HDAC Complex Protein BHC110 or KDM1A or EC 1.) - Pipeline ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.